David Nikodem, Ph.D. | Chief Executive Officer
David Nikodem joined AltheaDx in December 2018 as Interim CEO and was appointed full-time CEO in January 2020. He has served on the Board of Directors since December 2015.
Prior to AltheaDx, David was a senior representative of Ally Bridge Group, a Hong Kong based investment fund focused on Healthcare. During his 5+ years at Ally Bridge, David played an integral role in not only the growth of the Fund, but also the Fund’s biopharmaceutical investments by sourcing, leading, managing and serving on the boards of numerous biopharmaceutical portfolio companies. David has more than 13 years of experience in capital markets focused on biotechnology and healthcare companies; he began his Wall Street career in 2001. Since mid-2018, David has served as a consultant/part-time VP of US Operations for Inventiva Pharma, a France-based biotechnology company focused on NASH.
David holds undergraduate degrees in Chemistry, and English Language and Literature from the University of Virginia, and a PhD in biochemistry and molecular biology from Georgetown University. He conducted basic science research at the National Institutes of Health for 8 years and was also a patent examiner at the United States Patent and Trademark Office in Washington, D.C for 1 year.
Feng Cao, Ph.D. | Chief Operating Officer
Feng Cao joined AltheaDx in February 2015 with over fifteen years of experience in the molecular diagnostics space. Before expanding to lead Operations in April 2018, Feng was AltheaDx’s VP of Informatics, where he was responsible for the combined use of genetics, algorithm, and analytics to improve our IDgenetix® tests.
Prior to joining AltheaDx, Feng held management positions at Hologic where he launched the Invader Call Reporter® product line for molecular diagnostic IVD tests such as Cystic Fibrosis 510(k), Factor II/V 510(k), and HPV PMA. Prior to the acquisition of Third Wave Technologies by Hologic, Feng worked with a team of scientists on sequence analysis, SNP selection, assay design, and order generation for over 500,000 SNPs in support of the successful completion of the International HapMap Project.
Feng earned his doctorate in Cell Biology from Medical College of Wisconsin, his master’s degree in Computer Science from Marquette University, and his bachelor’s degree in Biology from Peking University.
Adrianna Ravenscroft | Laboratory Manager
With 8+ years of experience as a licensed Clinical Laboratory Scientist, Adrianna Ravenscroft provides the know-how for managing a CLIA lab since she joined AltheaDx in 2014.
Previous experience includes positions at UC San Diego Health System and Sharp Healthcare.
Adrianna obtained a BA in Biology from University of Montana and her Clinical Laboratory Science Internship from UCSD.
Curtis McGuyer, M.D. | Laboratory Director
Dr. Curtis McGuyer joined AltheaDx in January 2019 as our Laboratory Director. Curtis is also the Southwest Regional Commissioner for Laboratory Accreditation at College of American Pathologists (CAP).
After fulfilling his military service obligation, Curtis entered private practice and for 28 years worked as a community hospital pathologist in San Diego, California. His practice is now focused on clinical pathology, providing medical directorship to reference laboratories in San Diego.
Curtis received his M.D. from Baylor College of Medicine and his BS in Chemistry from University of Texas at El Paso. His residency was at Naval Hospital San Diego, where he completed his training in anatomic and clinical pathology. He is board-certified in both anatomic and clinical pathology, as well as cytopathology.